Phaseline

Companies › F2G

F2G: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Olorofim (F901318)
Dihydroorotate dehydrogenase (quinone), mitochondrial inhibitor
FKBP12Phase 3Invasive Aspergillosis; Coccidioidal Meningitis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05101187Olorofim (F901318)Phase 3Invasive AspergillosisInfectious diseaseNov 2025
NCT07385638Olorofim (F901318)Phase 2Coccidioidal MeningitisInfectious diseaseMar 2027

Targets

FKBP12 (1)

Companies with the same targets

–

Companies built like this

TCM Biotech International Vivacelle Bio Ansun Biopharma SymBio Pharmaceuticals Baxis Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.